Inspiremd enrolls and treats first patients at ballad health system in u.s. registration c-guardian clinical trial of cguard eps

Tel aviv, israel, july 23, 2021 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) device for the treatment of carotid artery disease (cad) and stroke prevention, today announces the initiation of enrollment and successful completion of the first cases of the company's u.s. registration c-guardian trial of cguard eps.
NSPR Ratings Summary
NSPR Quant Ranking